US FDA accepts Pfizer ’s sNDA for Xeljanz to treat ulcerative colitis
The US Food and Drug Administration (FDA) has accepted for filing Pfizer ’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate), an investigational oral solution to treat adult patients affected with moderately to severely activ…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news